Literature DB >> 24371640

Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature.

Hanane Inrhaoun1, Ibrahim Elghissassi2, Maya Gutierrez1, Etienne Brain1, Hassan Errihani2.   

Abstract

► We report a case of recurrent vulvar carcinoma with a good response to erlotinib. ► Treatment was well tolerated with no serious side effects. ► Further evaluation of this new therapeutic approach may be warranted.

Entities:  

Keywords:  EGFR; Erlotinib; Vulvar carcinoma

Year:  2012        PMID： 24371640      PMCID： PMC3861161          DOI： 10.1016/j.gynor.2012.07.002

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  9 in total

Review 1.  Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy.

Authors:  Elizabeth S Henson; Spencer B Gibson
Journal:  Cell Signal       Date:  2006-05-24       Impact factor: 4.315

2.  Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival.

Authors:  G A Johnson; R Mannel; M Khalifa; J L Walker; M Wren; K W Min; D M Benbrook
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

3.  Chemotherapy of squamous cell carcinoma of the vulva: a review.

Authors:  G Deppe; C J Cohen; H W Bruckner
Journal:  Gynecol Oncol       Date:  1979-06       Impact factor: 5.482

4.  Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").

Authors:  Mika Fukutome; Katsuya Maebayashi; Sachiko Nasu; Kaori Seki; Norio Mitsuhashi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-10-01       Impact factor: 7.038

5.  EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction.

Authors:  M H M Oonk; G H de Bock; D J van der Veen; K A Ten Hoor; J A de Hullu; H Hollema; A G J van der Zee
Journal:  Gynecol Oncol       Date:  2006-09-11       Impact factor: 5.482

6.  Decreased survival in EGFR gene amplified vulvar carcinoma.

Authors:  Whitfield B Growdon; Susan L Boisvert; Sara Akhavanfard; Esther Oliva; Dora C Dias-Santagata; Sakiko Kojiro; Neil S Horowitz; A John Iafrate; Darrell R Borger; Bo R Rueda
Journal:  Gynecol Oncol       Date:  2008-09-03       Impact factor: 5.482

7.  Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.

Authors:  S D Richard; T C Krivak; S Beriwal; K K Zorn
Journal:  Int J Gynecol Cancer       Date:  2007-11-16       Impact factor: 3.437

8.  Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.

Authors:  Alexander Olawaiye; Lisa M Lee; Carolyn Krasner; Neil Horowitz
Journal:  Gynecol Oncol       Date:  2007-06-11       Impact factor: 5.482

9.  Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study.

Authors:  G Lupi; F Raspagliesi; R Zucali; R Fontanelli; D Paladini; R Kenda; F di Re
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860
  9 in total
  1 in total

Review 1.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.